Through UALCAN and TCGA databases, we found that MPV17 was upregulated in most tumors, and its expression in LIHC patients had a great association with carcinoma stages, tumor grades, nodal metastasis status, gender, histological subtypes, and TP53 mutation status, implying that MPV17 might act as an oncogene in LIHC. This evidence concerns the gene MPV17 and carcinoma.